Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.
Wu
Jia-Jen
JJ
Tsai
Tsen-Fang
TF
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000503:physiopathology; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012008:Recurrence; D018570:Risk Assessment; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001786:Blood Glucose; D013453:Sulfonylurea Compounds; D014409:Tumor Necrosis Factor-alpha; C057619:glimepiride; D000068879:Adalimumab